Genentech
Hanmi Pharmaceutical raided over insider trading suspicions
October 17, 2016Sales and Marketing Boehringer Ingelheim, Genentech, Hanmi Pharmaceutical, south korea
At the end of September, we reported on a busy 24-hour for Hanmi Pharmaceutical, as they secured a deal with …
Hanmi Pharma shares crash after shock contract termination
September 30, 2016Manufacturing and Production, Medical Communications, Research and Development Boehringer Ingelheim, Genentech, Germany, HM61713, Hanmi Pharmaceutical, Tagrisso, south korea
News broke on 29 September that Hanmi Pharma, South Korea’s leading drug maker, had signed a $910 million deal with …
Study shows promise for Venclexta in acute myelogenous leukaemia
August 12, 2016Research and Development, Sales and Marketing AbbVie, Genentech, Roche, Venclexta, venetoclax
A study published in Cancer Discovery, the journal of the American Association for Cancer Research, suggests that Vencletxa (venetoclax) is …
Darzalex to be trialled in combination with atezolizumab in multiple myeloma and solid tumours
March 22, 2016Research and Development Genentech, Genmab, Janssen, Roche, atezolizumab, clnical trials, multiple myeloma, phase ib, solid tumours, tumour
Phase Ib clinical studies are set to begin, which will evaluate Darzalex (daratumumab) in combination with atezolizumab in a solid …
Genentech cancer immunotherapy gets Priority FDA Review in bladder cancer
March 15, 2016Manufacturing and Production, Research and Development FDA, Genentech, Roche, atezolizumab, bladder cancer, priority review
The US FDA has granted Roche subsidiary Genentech a Priority Review for atezolizumab in treating advanced bladder cancer, whose disease …
FDA gives Roche MS drug breakthrough status
February 17, 2016Research and Development Genentech, MS, Roche
Roche subsidiary Genentech has been awarded US Food and Drug Administration (FDA) Breakthrough Therapy Designation for its drug Ocrevus (ocrelizumab) …
Roche lung cancer drug Alecensa gets rapid US approval
December 14, 2015Sales and Marketing Alecensa, FDA, Genentech, Roche, accelerated approval, alectinib, lung cancer, non-small cell lung cancer
The US health watchdog has approved Alecensa, a drug for people with certain types of non-small cell lung cancer manufactured …
FDA approves Roche skin cancer combination
November 11, 2015Research and Development, Sales and Marketing Cotellic, FDA, Genentech, Roche, Zelboraf, cobimetinib, melanoma, skin cancer, vemurafenib
The FDA has approved the skin cancer drug Cotellic for certain forms of melanoma in combination with another Roche cancer …
Positive late-stage results for Genentech’s ocrelizumab in different forms of MS
October 8, 2015Research and Development ECTRIMS, Genentech, MS, Roche, multiple sclerosis, ocrelizumab
Roche’s biotech arm Genentech has presented ‘transformative’ data at an international multiple sclerosis conference on its investigational drug ocrelizumab. Ocrelizumab …
Genentech’s ocrelizumab shows efficacy in phase III trial
September 30, 2015Research and Development Genentech, MS, Roche, ocrelizumab
Roche subsidiary Genentech has announced positive results from a pivotal phase III study of its investigational medicine ocrelizumab in people …
Genentech Haemophilia therapy gets FDA breakthrough designation
September 4, 2015Research and Development, Sales and Marketing Genentech, Roche, haemophilia a
Roche subsidiary Genentech has been granted FDA breakthrough therapy designation for its ACE910 (RG6013, RO5534262) haemophilia A therapy. The designation …
Roche lung cancer therapy succeeds in mid-stage trial
August 17, 2015Research and Development, Sales and Marketing Genentech, Roche, atezolizumab, lung cancer, non-small cell lung cancer
Roche’s biotech arm Genentech has scored positive results in a pivotal Phase II study of its investigational cancer immunotherapy atezolizumab. …
Roche posts positive mid-stage trial results for atezolizumab
July 13, 2015Research and Development Genentech, PD-L1, Phase II, Roche, anti-PD-L1, atezolizumab, clinical trial, immuno-oncology, personalised medicine
A cancer drug in development by Roche has performed well in a mid-phase clinical trial – prompting the Swiss firm …
Drug development showcasing at AACR conference
April 13, 2015Research and Development, Sales and Marketing American Association of Cancer Research, AstraZeneca, Bayer, Genentech, Novartis, aacr
This month’s American Association of Cancer Research conference is set to showcase the latest studies in oncology. Roche’s biotech subsidiary …
Bioinformatics pioneer joins 23andMe from Genentech
April 13, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 23andME, Genentech, Robert Gentleman
California-based personal genetics firm 23andMe has appointed Robert Gentleman to be its vice president of computational biology. The company is …
Latest content
Five Facts about cardiovascular disease
